KRAS and colorectal neoplasm: KRAS is an intracellular signaling molecule, and about 40% of colorectal tumors have KRAS mutations, so identifying the key signaling pathways affected by KRAS mutations help us understand how to conduct drug-targeted therapy (Andreyev et al., 2001).